{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T19:45:20Z","timestamp":1776282320917,"version":"3.50.1"},"reference-count":27,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>It is believed that fibroblast growth factor 23 (FGF23) can become an early biomarker of chronic kidney disease progression. Data on FGF23 age dependency are inconsistent. We present the results of the cross-sectional study concerning FGF23 levels in healthy Polish children.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Material and methods<\/jats:title>\n                  <jats:p>This study was conducted in 121 children aged 0\u201318 years. Kidney function and intact FGF23 levels in serum were assessed. Differences between age groups and according to gender were analysed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The difference in FGF23 between age groups and according to gender was statistically insignificant. In the youngest and the oldest group, a trend to higher FGF23 levels was observed. FGF23 level in girls tended to be higher than boys, apart from the age group between 1 and 4 years. There was a negative correlation between eGFR and FGF23 (<jats:italic>r<\/jats:italic> = \u22120.26, <jats:italic>p<\/jats:italic> &lt; 0.05)\u2009\u2013\u2009strong in girls (<jats:italic>r<\/jats:italic> = \u22120.38, <jats:italic>p<\/jats:italic> &lt; 0.05), but not in boys. In each age group, we found no significant correlation between eGFR and FGF23.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study supports the evidence that the FGF23 level in paediatric population is not age or sex dependent. The results can serve as a reference point under clinical conditions and for other studies on the topic.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/med-2021-0288","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T20:12:28Z","timestamp":1625602348000},"page":"1022-1027","source":"Crossref","is-referenced-by-count":12,"title":["Serum intact fibroblast growth factor 23 in healthy paediatric population"],"prefix":"10.1515","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6613-1642","authenticated-orcid":false,"given":"Malgorzata","family":"Stanczyk","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Immunology and Nephrology, Polish Mother\u2019s Memorial Hospital Research Institute , Rzgowska 281\/289 , Lodz 93-338 , Poland"},{"name":"Department of Pediatrics, Preventive Cardiology and Immunology of Developmental Age , Medical University of Lodz , Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slawomir","family":"Chrul","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Immunology and Nephrology, Polish Mother\u2019s Memorial Hospital Research Institute , Lodz 93-338 , Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystyna","family":"Wyka","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Oncology and Hematology, Medical University of Lodz , Lodz , Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Tkaczyk","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Immunology and Nephrology, Polish Mother\u2019s Memorial Hospital Research Institute , Lodz 93-338 , Poland"},{"name":"Department of Pediatrics, Preventive Cardiology and Immunology of Developmental Age , Medical University of Lodz , Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"key":"2022091918191502517_j_med-2021-0288_ref_001","doi-asserted-by":"crossref","unstructured":"Consortium A. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26(3):345\u20138.","DOI":"10.1038\/81664"},{"key":"2022091918191502517_j_med-2021-0288_ref_002","doi-asserted-by":"crossref","unstructured":"Gattineni J, Baum M. Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol. 2010;25(4):591\u2013601.","DOI":"10.1007\/s00467-009-1273-z"},{"key":"2022091918191502517_j_med-2021-0288_ref_003","doi-asserted-by":"crossref","unstructured":"Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson KB, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007;195(1):125\u201331.","DOI":"10.1677\/JOE-07-0267"},{"key":"2022091918191502517_j_med-2021-0288_ref_004","doi-asserted-by":"crossref","unstructured":"Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19(3):429\u201335.","DOI":"10.1359\/JBMR.0301264"},{"key":"2022091918191502517_j_med-2021-0288_ref_005","doi-asserted-by":"crossref","unstructured":"Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444(7120):770\u20134.","DOI":"10.1038\/nature05315"},{"key":"2022091918191502517_j_med-2021-0288_ref_006","doi-asserted-by":"crossref","unstructured":"Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology. 2002;143(8):3179\u201382.","DOI":"10.1210\/endo.143.8.8795"},{"key":"2022091918191502517_j_med-2021-0288_ref_007","doi-asserted-by":"crossref","unstructured":"Bacchetta J, Dubourg L, Harambat J, Ranchin B, Abou-Jaoude P, Arnaud S, et al. The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab. 2010;95(4):1741\u20138.","DOI":"10.1210\/jc.2009-1576"},{"key":"2022091918191502517_j_med-2021-0288_ref_008","unstructured":"Ziolkowska H, Okarska-Napierala M, Stelmaszczyk-Emmel A, Gorska E, Zachwieja K, Zurowska A, et al. Serum fibroblast growth factor 23 and calcium-phosphorus metabolism parameters in children with chronic kidney disease\u2009\u2013\u2009preliminary report. Dev Period Med. 2014;18(2):194\u2013202."},{"key":"2022091918191502517_j_med-2021-0288_ref_009","doi-asserted-by":"crossref","unstructured":"Portale AA, Wolf M, Juppner H, Messinger S, Kumar J, Wesseling-Perry K, et al. Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol. 2014;9(2):344\u201353.","DOI":"10.2215\/CJN.05840513"},{"key":"2022091918191502517_j_med-2021-0288_ref_010","doi-asserted-by":"crossref","unstructured":"Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, Choukroun G, et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int. 2012;23(7):2017\u201325.","DOI":"10.1007\/s00198-011-1838-0"},{"key":"2022091918191502517_j_med-2021-0288_ref_011","doi-asserted-by":"crossref","unstructured":"Gutierrez OM. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the \u201ctrade-off\u201d hypothesis. Clin J Am Soc Nephrol. 2010;5(9):1710\u20136.","DOI":"10.2215\/CJN.02640310"},{"key":"2022091918191502517_j_med-2021-0288_ref_012","doi-asserted-by":"crossref","unstructured":"Fischer DC, Mischek A, Wolf S, Rahn A, Salweski B, Kundt G, et al. Paediatric reference values for the c-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase. Ann Clin Biochem. 2012;49(Pt 6):546\u201353.","DOI":"10.1258\/acb.2012.011274"},{"key":"2022091918191502517_j_med-2021-0288_ref_013","doi-asserted-by":"crossref","unstructured":"Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA. 2001;98(11):6500\u20135.","DOI":"10.1073\/pnas.101545198"},{"key":"2022091918191502517_j_med-2021-0288_ref_014","doi-asserted-by":"crossref","unstructured":"Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003;348(17):1656\u201363.","DOI":"10.1056\/NEJMoa020881"},{"key":"2022091918191502517_j_med-2021-0288_ref_015","doi-asserted-by":"crossref","unstructured":"Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393\u2013408.","DOI":"10.1172\/JCI46122"},{"key":"2022091918191502517_j_med-2021-0288_ref_016","doi-asserted-by":"crossref","unstructured":"Ix JH, Shlipak MG, Wassel CL, Whooley MA. Fibroblast growth factor-23 and early decrements in kidney function: the heart and soul study. Nephrol Dial Transplant. 2010;25(3):993\u20137.","DOI":"10.1093\/ndt\/gfp699"},{"key":"2022091918191502517_j_med-2021-0288_ref_017","doi-asserted-by":"crossref","unstructured":"Bergwitz C, Juppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med. 2010;61:91\u2013104.","DOI":"10.1146\/annurev.med.051308.111339"},{"key":"2022091918191502517_j_med-2021-0288_ref_018","doi-asserted-by":"crossref","unstructured":"National Kidney F. K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1\u2013201.","DOI":"10.1016\/S0272-6386(03)00905-3"},{"key":"2022091918191502517_j_med-2021-0288_ref_019","doi-asserted-by":"crossref","unstructured":"Gkentzi D, Efthymiadou A, Kritikou D, Chrysis D. Fibroblast growth factor 23 and Klotho serum levels in healthy children. Bone. 2014;66:8\u201314.","DOI":"10.1016\/j.bone.2014.05.012"},{"key":"2022091918191502517_j_med-2021-0288_ref_020","doi-asserted-by":"crossref","unstructured":"Mitchell DM, Juppner H, Burnett-Bowie SM. FGF23 is not associated with age-related changes in phosphate, but enhances renal calcium reabsorption in girls. J Clin Endocrinol Metab. 2017;102(4):1151\u201360.","DOI":"10.1210\/jc.2016-4038"},{"key":"2022091918191502517_j_med-2021-0288_ref_021","doi-asserted-by":"crossref","unstructured":"Berndt T, Thomas LF, Craig TA, Sommer S, Li X, Bergstralh EJ, et al. Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Proc Natl Acad Sci U S A. 2007;104(26):11085\u201390.","DOI":"10.1073\/pnas.0704446104"},{"key":"2022091918191502517_j_med-2021-0288_ref_022","doi-asserted-by":"crossref","unstructured":"Giral H, Caldas Y, Sutherland E, Wilson P, Breusegem S, Barry N, et al. Regulation of rat intestinal Na-dependent phosphate transporters by dietary phosphate. Am J Physiol Renal Physiol. 2009;297(5):F1466\u201375.","DOI":"10.1152\/ajprenal.00279.2009"},{"key":"2022091918191502517_j_med-2021-0288_ref_023","doi-asserted-by":"crossref","unstructured":"Braithwaite V, Jarjou LM, Goldberg GR, Prentice A. Iron status and fibroblast growth factor-23 in Gambian children. Bone. 2012;50(6):1351\u20136.","DOI":"10.1016\/j.bone.2012.03.010"},{"key":"2022091918191502517_j_med-2021-0288_ref_024","doi-asserted-by":"crossref","unstructured":"Braithwaite V, Prentice AM, Doherty C, Prentice A. FGF23 is correlated with iron status but not with inflammation and decreases after iron supplementation: a supplementation study. Int J Pediatr Endocrinol. 2012;2012(1):27.","DOI":"10.1186\/1687-9856-2012-27"},{"key":"2022091918191502517_j_med-2021-0288_ref_025","doi-asserted-by":"crossref","unstructured":"Durham BH, Joseph F, Bailey LM, Fraser WD. The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays. Ann Clin Biochem. 2007;44(Pt 5):463\u20136.","DOI":"10.1258\/000456307781646102"},{"key":"2022091918191502517_j_med-2021-0288_ref_026","unstructured":"Fassbender WJ, Brandenburg V, Schmitz S, Sandig D, Simon SA, Windolf J, et al. Evaluation of human fibroblast growth factor 23 (FGF-23) c-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patients. Clin Lab. 2009;55(3\u20134):144\u201352."},{"key":"2022091918191502517_j_med-2021-0288_ref_027","doi-asserted-by":"crossref","unstructured":"Devaraj S, Duncan-Staley C, Jialal I. Evaluation of a method for fibroblast growth factor-23: a novel biomarker of adverse outcomes in patients with renal disease. Metab Syndr Relat Disord. 2010;8(6):477\u201382.","DOI":"10.1089\/met.2010.0030"}],"container-title":["Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/med-2021-0288\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/med-2021-0288\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T18:35:06Z","timestamp":1663612506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/med-2021-0288\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,7,15]]},"published-print":{"date-parts":[[2021,7,15]]}},"alternative-id":["10.1515\/med-2021-0288"],"URL":"https:\/\/doi.org\/10.1515\/med-2021-0288","relation":{},"ISSN":["2391-5463"],"issn-type":[{"value":"2391-5463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]}}}